Subscribe to our Newsletters !!
Few developments in science and technology have be
Even well‑validated LC–UV methods can produ
The recent rabies death of an 11 year old Canadian
Alembic Pharmaceutica
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Mi
Depression is type of sad, anxious, empty, hopeless, helpless, and irritating conditions now most commons in young age even middle age groups and according to sources, affecting millions of people worldwide and costing the US alone over $200 billion per year. The most common treatments for depression are cognitive behaviour therapy (CBT) and antidepressants.
Researcher recently detected compound isolated from magic mushrooms named: Psilocybin — a hallucinogenic compound may help in reducing depression. The concern research appeared in The Lancet Psychiatry.
"This is the first time that psilocybin has been investigated as a potential treatment for major depression," says lead author Dr Robin Carhart-Harris, Imperial College London, London, UK. "Treatment-resistant depression is common, disabling and extremely difficult to treat. New treatments are urgently needed, and our study shows that psilocybin is a promising area of future research. The results are encouraging and we now need larger trials to understand whether the effects we saw in this study translate into long-term benefits, and to study how psilocybin compares to other current treatments."
Researchers also informed the warning that right strong conclusion of beneficial activity of psilocybin not detected however further research needed in this field.
Story Source: The Lancet with article entitled: Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA, Authored by: Michael C Mithoefer, Charles S Grob, Timothy D Brewerton
